Veru (NASDAQ:VERU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Veru (NASDAQ:VERU) from a sell rating to a hold rating in a research note released on Saturday morning.

Several other equities analysts have also commented on VERU. Canaccord Genuity Group began coverage on shares of Veru in a research report on Thursday, December 18th. They issued a “buy” rating and a $25.00 price objective for the company. Oppenheimer restated an “outperform” rating on shares of Veru in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Veru has an average rating of “Moderate Buy” and an average target price of $25.00.

Veru Price Performance

Veru stock opened at $2.29 on Friday. Veru has a 1-year low of $2.11 and a 1-year high of $14.20. The business has a fifty day moving average price of $2.86 and a 200-day moving average price of $4.03. The stock has a market capitalization of $36.75 million, a price-to-earnings ratio of -1.04 and a beta of -1.00.

Institutional Trading of Veru

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Catalyst Funds Management Pty Ltd acquired a new position in Veru during the second quarter valued at $36,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Veru during the 3rd quarter valued at about $38,000. Allworth Financial LP acquired a new position in shares of Veru in the 2nd quarter valued at about $45,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Veru in the third quarter worth about $47,000. Finally, XTX Topco Ltd acquired a new stake in Veru during the second quarter worth about $49,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.